A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
=== Weight loss === Excess body weight is thought to be an important cause of sleep apnea. People who are overweight have more tissues in the back of their throat which can restrict the airway, especially when sleeping. In weight loss studies of overweight individuals, those who lose weight show reduced apnea frequencies and improved apnoea–hypopnoea index (AHI). Weight loss effective enough to relieve obesity hypoventilation syndrome (OHS) must be 25–30% of body weight. For some obese people, it can be difficult to achieve and maintain this result without bariatric surgery.
The nine eastern lowland departments, comprising about 54% of Colombia's area, have less than 6% of the population. Traditionally a rural society, movement to urban areas was very heavy in the mid-20th century, and Colombia is now one of the most urbanized countries in Latin America. The urban population increased from 31% of the total in 1938 to nearly 60% in 1973, and by 2014 the figure stood at 76%. The population of Bogotá alone has increased from just over 300,000 in 1938 to approximately 8 million today. In total 72 cities now have populations of 100,000 or more (2015). As of 2012 Colombia has the world's largest populations of internally displaced persons (IDPs), estimated to be up to 4.9 million people. The life expectancy was 74.8 years in 2015, and infant mortality was 13.1 per thousand in 2016. In 2015, 94.58% of adults and 98.66% of youth are literate and the government spends about 4.49% of its GDP on education. Colombia is a highly urbanized country with 77.1% of the population living in urban areas. The largest cities in the country are Bogotá, with 7,387,400 inhabitants, Medellín, with 2,382,399 inhabitants, Cali, with 2,172,527 inhabitants, and Barranquilla, with 1,205,284 inhabitants.
=== Subcellular localization === C3orf62 is predicted to be localized in the nucleus. The k-nearest neighbors algorithm predicts C3orf62 to be classified as follows: k=9/23; 69.6% nuclear, 13.0% mitochondrial, 13.0% cytoskeletal, 4.3% cytoplasmic.
Sources: en.wikipedia.org
Nights were spent camping on riverbanks, where hammocks were usually slung between trees or, when trees were absent, from canoe paddles or on ox-hides. This exposed the expedition to risks from snakes, alligators, and jaguars, which were especially prevalent and feared by local Natives. Nighttime was often unsettled due to animal activity, including monkeys, peccaries, sloths, and birds.Shortly after departure, a sudden squall nearly overturned the canoe, but a shift in wind stabilized the vessel. The following morning, the expedition encountered a Carib family traveling from the mouth of the Orinoco to collect turtle eggs, an event that attracted hundreds of Natives from various tribes and a few white traders. The eggs were rendered for oil, used for cooking and lighting, though overharvesting threatened the turtle population. At the Island of the Tortoises, Native tribes gathered annually to harvest turtle eggs, each tribe distinguished by unique body paint. Humboldt observed the process and noted that the previous Jesuit supervisors had ensured some eggs were left to hatch, but that their successors, the Franciscans, did not exercise such care, causing a decline in the turtle population. The Native crew from San Fernando departed at the turtle islands, as they lacked experience with the rapids ahead. The expedition switched to a smaller, less comfortable canoe, fashioned from a single tree trunk, which further limited space and increased exposure to environmental discomforts.
=== Radiological cleanup === A radiological survey of Enewetak was conducted from 1972 to 1973. In 1977, the United States military began decontamination of Enewetak and other islands. During the three-year, US$100 million cleanup process, the military mixed more than 80,000 cubic meters (100,000 cu yd) of contaminated soil and debris from the islands with Portland cement and buried it in an atomic blast crater on the northern end of the atoll's Runit Island. The material was placed in the 9.1-meter (30 ft) deep, 110-meter (360 ft) wide crater created by the May 5, 1958, "Cactus" nuclear weapons test. A dome composed of 358 concrete panels, each 46 centimeters (18 in) thick, was constructed over the material. The final cost of the cleanup project was US$239 million. The United States government declared the southern and western islands in the atoll safe for habitation in 1980, and residents of Enewetak returned that same year. The military members who participated in that cleanup mission are suffering from many health issues, but the U.S. Government refused to provide health coverage until 2022 with the passage of the Honoring our PACT Act. The 2000 environmental restoration award included funds for additional cleanup of radioactivity on Enewetak. Rather than scrape the topsoil off, replace it with clean topsoil, and create another radioactive waste repository dome at some site on the atoll (a project estimated to cost US$947 million), most areas still contaminated on Enewetak were treated with potassium.
Tryptophan, arginine, cysteine and charged amino acids, like aspartic and glutamic acid, are poorly removed. ERAP1's trimming efficiency can also be influenced by the internal sequence of the peptide, with preferences for hydrophobic and positively charged residues.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.